Coronavirus | Covovax trials begin in India, hope to launch it by September 2021: Adar Poonawalla
The Hindu
The vaccine is made through a partnership with America’s Novavax and Serum Institute of India
Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of COVID-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year. In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India. "Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Mr Poonawalla said in a tweet.More Related News
Around 440 MBBS graduates of 2021 are not required to undergo one year of compulsory rural service as per the bond signed by them while joining the medical course through government-quota seats in 2015 as the High Court of Karnataka has said the law, enacted in 2012 for mandatory rural service, remained unenforced for 10 years as it was published in the official gazette only in July 2022.